slide 1 of 1


How to build a leading-practice RWE program to inform Market Access and value-based drug contracting




Aetion_Carolyn_012_bw (2)

Carolyn Magill

CEO, Aetion

Headshot_Kelly Guntrum copy-1

Kelly Guntrum

Head of U.S. Value & Innovation Contracts and Partnerships, UCB

liz turner headshot

Liz Turner

Vice President, Global Market Access, Arena Pharmaceuticals

What you'll learn


Current trends, and what to expect next, in the use of RWE to inform innovative contracting between pharma manufacturers and payers.


Real-life examples of how biopharma companies are using RWE to enable value-based care initiatives, including the stage of lifecycle where discussions begin.


How to build platform-based infrastructure and processes to enable these types of contracts; for instance, using rapid-cycle analytics™ to quickly and iteratively run analyses in a transparent manner that enables trust with U.S. payers.


Watch Now

Listen as experts from Aetion and industry explore emerging trends in the use of RWE to inform market access and innovative managed care contracting.